SGLT2 vs GLP1 for Cardiovascular Prevention

Annals On Call Podcast
20/12/2021 23 min

Listen "SGLT2 vs GLP1 for Cardiovascular Prevention"

Descargar episodio Ver en sitio original

Episode Synopsis

Dr. Centor discusses the use of sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes with Dr. Elisabetta Patorno.

More episodes of the podcast Annals On Call Podcast

Complications Associated With Transvenous Cardiac Implantable Devices 15/12/2025
Cost-Effectiveness of Weight Loss Drugs for Knee Osteoarthritis 01/12/2025
Palliative Care: A Family Perspective 17/11/2025
What You May Have Missed in 2024: Part 3 03/11/2025
What You May Have Missed in 2024 - Part 2 20/10/2025
High-Concentration Cannabinoids: Are They Safe? 06/10/2025
What You May Have Missed in 2024: Part 1 15/09/2025
Fibrillation - When Ablation is the Way to Go 01/09/2025
Semaglutide Versus Dulaglutide or Empagliflozin: Death and Cardiovascular Outcomes for Patients With Type 2 Diabetes 18/08/2025
Comparison of Dose Escalation Versus Switching to Tirzepatide When Diabetes Control is Inadequate on Dulaglutide 04/08/2025
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA